AU757357B2 - Methods and compositions for enhancing immune response and for the production of in vitro mabs - Google Patents

Methods and compositions for enhancing immune response and for the production of in vitro mabs Download PDF

Info

Publication number
AU757357B2
AU757357B2 AU14548/99A AU1454899A AU757357B2 AU 757357 B2 AU757357 B2 AU 757357B2 AU 14548/99 A AU14548/99 A AU 14548/99A AU 1454899 A AU1454899 A AU 1454899A AU 757357 B2 AU757357 B2 AU 757357B2
Authority
AU
Australia
Prior art keywords
antigen
cells
specific
immune
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU14548/99A
Other languages
English (en)
Other versions
AU1454899A (en
Inventor
Giulio F Paciotti
Lawrence Tamarkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytimmune Sciences Inc
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Publication of AU1454899A publication Critical patent/AU1454899A/en
Application granted granted Critical
Publication of AU757357B2 publication Critical patent/AU757357B2/en
Priority to AU2003204353A priority Critical patent/AU2003204353B2/en
Priority to AU2006235956A priority patent/AU2006235956B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU14548/99A 1997-11-10 1998-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs Ceased AU757357B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003204353A AU2003204353B2 (en) 1997-11-10 2003-05-23 Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2006235956A AU2006235956B2 (en) 1997-11-10 2006-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6515597P 1997-11-10 1997-11-10
US60/065155 1997-11-10
US7581198P 1998-02-24 1998-02-24
US60/075811 1998-02-24
US10745598P 1998-11-06 1998-11-06
US60/107455 1998-11-06
PCT/US1998/023957 WO1999024066A2 (en) 1997-11-10 1998-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2003204353A Division AU2003204353B2 (en) 1997-11-10 2003-05-23 Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2006235956A Division AU2006235956B2 (en) 1997-11-10 2006-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs

Publications (2)

Publication Number Publication Date
AU1454899A AU1454899A (en) 1999-05-31
AU757357B2 true AU757357B2 (en) 2003-02-20

Family

ID=27370737

Family Applications (3)

Application Number Title Priority Date Filing Date
AU14548/99A Ceased AU757357B2 (en) 1997-11-10 1998-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2003204353A Ceased AU2003204353B2 (en) 1997-11-10 2003-05-23 Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2006235956A Ceased AU2006235956B2 (en) 1997-11-10 2006-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2003204353A Ceased AU2003204353B2 (en) 1997-11-10 2003-05-23 Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2006235956A Ceased AU2006235956B2 (en) 1997-11-10 2006-11-10 Methods and compositions for enhancing immune response and for the production of in vitro mabs

Country Status (8)

Country Link
EP (1) EP1039933B8 (https=)
JP (3) JP4588210B2 (https=)
AT (1) ATE317269T1 (https=)
AU (3) AU757357B2 (https=)
CA (1) CA2309602C (https=)
DE (1) DE69833455T2 (https=)
NZ (1) NZ504292A (https=)
WO (1) WO1999024066A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790167B2 (en) 1997-11-10 2010-09-07 Cyt Immune Sciences, Inc. Methods and compositions for enhancing immune response and for the production of in vitro Mabs
US7951614B2 (en) 2003-12-02 2011-05-31 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US7960145B2 (en) 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
US8137989B2 (en) 1994-03-18 2012-03-20 Cytimmune Sciences, Inc. Method for delivering a cytokine using a colloidal metal

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
EP1133994A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA"
CA2448607C (en) * 2001-04-30 2013-01-22 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
US8877156B2 (en) 2007-06-26 2014-11-04 New York University Contrast agents anchored by thiols on nanoparticles
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
JP5364310B2 (ja) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021288A1 (en) * 1993-03-18 1994-09-29 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
AU1394099A (en) * 1997-11-10 1999-05-31 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001461A1 (en) * 1980-07-18 1982-05-13 Leland Stanford Junior Univ Human hybridomas,precursors and products
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
JPS61104796A (ja) * 1984-10-26 1986-05-23 Chemo Sero Therapeut Res Inst モノクロ−ナル抗体の製造方法
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
JPH07227299A (ja) * 1994-02-14 1995-08-29 Kyoto Daiichi Kagaku:Kk Ｄｎａの特定塩基配列の検出方法及びその装置
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
JPH09107980A (ja) * 1995-08-17 1997-04-28 Japan Tobacco Inc 新規生理活性タンパク

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021288A1 (en) * 1993-03-18 1994-09-29 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
AU1394099A (en) * 1997-11-10 1999-05-31 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137989B2 (en) 1994-03-18 2012-03-20 Cytimmune Sciences, Inc. Method for delivering a cytokine using a colloidal metal
US7790167B2 (en) 1997-11-10 2010-09-07 Cyt Immune Sciences, Inc. Methods and compositions for enhancing immune response and for the production of in vitro Mabs
US7951614B2 (en) 2003-12-02 2011-05-31 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US7960145B2 (en) 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies

Also Published As

Publication number Publication date
EP1039933B8 (en) 2006-12-20
JP2013014616A (ja) 2013-01-24
WO1999024066A3 (en) 1999-12-09
NZ504292A (en) 2003-03-28
CA2309602C (en) 2011-04-26
AU2006235956B2 (en) 2010-02-11
JP2002503639A (ja) 2002-02-05
JP2009292818A (ja) 2009-12-17
AU2006235956A1 (en) 2006-11-30
DE69833455D1 (de) 2006-04-20
AU1454899A (en) 1999-05-31
DE69833455T2 (de) 2006-10-19
EP1039933A2 (en) 2000-10-04
ATE317269T1 (de) 2006-02-15
EP1039933B1 (en) 2006-02-08
JP4588210B2 (ja) 2010-11-24
CA2309602A1 (en) 1999-05-20
AU2003204353B2 (en) 2006-08-10
WO1999024066A2 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
US7790167B2 (en) Methods and compositions for enhancing immune response and for the production of in vitro Mabs
US8435801B2 (en) Methods and compositions for the production of monoclonal antibodies
JP2013014616A (ja) 免疫応答を増強するため、およびインビトロでのモノクローナル抗体の産生のための方法および組成物
US20090035265A1 (en) Compositions and Methods for Targeted Delivery of Factors
CZ298670B6 (cs) Použití cinidla pro výrobu léciva pro prevenci a/nebo lécení autoimunní choroby nebo lidské T lymfocytární leukemie nebo odmítnutí implantátu, farmaceutický prostredek a kit obsahující tento prostredek
van Essen et al. Role of B cells in maintaining helper T–cell memory
EP1448216A2 (en) Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases
JP7086000B2 (ja) 体液性親和性の加速に関する方法及び組成物
AU2003231660B2 (en) Compositions and methods for targeted delivery of factors
JPH04500003A (ja) ブタ多クローン性抗体および単クローン性抗体
RU2242245C2 (ru) Искусственные микобактериальные частицы и противотуберкулезная вакцинная композиция на их основе
JP2009286808A (ja) 生物学的に活性な因子の標的化された送達のための組成物および方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)